Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Oncology|April 27, 2021
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting AnalysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Gastroenterology Report|May 24, 2021
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Liver Cancer|May 12, 2021
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Scientific Reports|July 15, 2021
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Journal of Gastroenterology and Hepatology|November 10, 2020
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weightingAtsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Scientific Reports|August 18, 2021
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective studyAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Cancer Reports (Hoboken, N.J.)|June 11, 2021
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experienceAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
European Journal of Gastroenterology & Hepatology|July 8, 2022
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Scientific Reports|May 19, 2022
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Pageof 17